News

Every day, millions of people worldwide live with chronic, serious or rare diseases – including cancer, for which there is often no cure or effective treatment.

Progress is only possible when we act together: doctors, scientists, patients, and society as a whole.

Clinical research is the key. It’s through medical studies that we develop new therapies and medications — giving hope, improving quality of life, and increasing the chances of healing.

To better understand how clinical trials work and why participation matters, Studien wirken provides clear and accessible insights.

But this progress depends on informed and courageous individuals who choose to participate in clinical trials. Without them, innovation stands still.
Together we can move research forward — because cancer needs collective action.

Last week, our live webinar on “Why do so many Alzheimer’s trials fail to deliver actionable insights?” took place on LinkedIn.

Our Founder & CEO, Prof. Matthias Günther and Dr. Nikola Cihoric, MD, RO, Founder & Chief Product Officer at Wemedoo, explored the challenges of current Alzheimer’s trials and discussed how meaningful insights can be improved.

If you missed the 30‑minute session, you can rewatch the full webinar anytime via the following YouTube link: VIDEO LINK

Latest data from our partner Quantified Imaging demonstrate that ASL‑MRI can reveal treatment response to Lecanemab after just 2 months. These perfusion‑based biomarkers show strong alignment with long‑term cognitive outcomes — a major step toward more reliable and efficient trial design.

In a field challenged by complex biology and heterogeneous patient profiles, advanced imaging offers a clearer, earlier window into therapeutic impact.

Wemedoo and mediri are hosting a joint 30‑minute live webinar, bringing together clinical, imaging, and data perspectives to examine why Alzheimer’s trials so often fall short — and what can be done differently.

Speakers:
Prof. Dr. Matthias Guenther, Founder & CEO, mediri
Dr. Nikola Cihoric, MD, RO, Founder & Chief Product Officer, Wemedoo

Live Webinar
January 29, 2026
12:00 – 12:30 CET

Join us to explore how imaging innovation can accelerate Alzheimer’s research.
Webinar LINK

We wish you and your loved ones a joyful Christmas and relaxing holidays. May the New Year 2026 bring you success, happiness, and new opportunities. Thank you for being a part of our journey this year.
We look forward to achieving great things together in the coming year.
Warmest wishes from all of us.

mTRIAL Release 3.5 is here!
We’re excited to announce the latest update to our medical image data management software. Among the new features, Automated defacing stands out:

– Designed for high-resolution head MRI scans
– Automatically detects and removes facial regions
– This results in improved pseudonymization

With this release, we’re taking another step forward in combining cutting-edge imaging technology with robust patient data protection.

Meet Wemedoo and mediri GmbH together at the 33rd BVMA Symposium 2025 in Munich!

Clinical trials are becoming more complex—but managing them doesn’t have to be. With interoperable systems and integrated imaging workflows, we’re simplifying study oversight from start to finish.

Join us at the BVAM (Bundesverband Medizinischer Auftragsinstitute e.V.) Symposium on November 21, 2025, and let’s discuss how our strategic partnership is shaping a more efficient future for clinical research.

Together with our strategic partner Wemedoo, we are integrating Wemedoo’s interoperable clinical data management system oomnia with mediri’s mTRIAL platform to bring greater efficiency to your next study.
Let’s connect in Munich!

On this International Day of Radiology, we celebrate the transformative power of medical imaging—and the people behind it.

At mediri, we’re committed to making the radiologist’s job easier, faster, and more precise. How? Through customized web-based forms tailored to each clinical study. Whether it’s a screening visit or an inclusion assessment, our tools help radiologists:

• Make faster decisions on patient eligibility
• Communicate results instantly with study sites
• Evaluate visits efficiently and assign patients to the correct study arm

By streamlining workflows and reducing administrative overhead, we empower radiologists to focus on what matters most: delivering high-quality insights that drive better patient outcomes.

Today, we honor the radiology community—and reaffirm our mission to support it with smart, intuitive technology.

Next Sneak Peek: the RANO-HGG Response Assessment.
Continuing our journey through the new mTRIAL release!

Designed with clarity and precision in mind, this report offers a comprehensive overview of:

• SPD analysis (sum of the products of diameters) of target lesions
• Thumbnails of target lesions for visual reference
• Status for non-target lesions
• Response classification based on imaging and clinical parameters
• A dynamic Lesion Progression Chart for longitudinal tracking

This new report brings structure and transparency to complex data, helping clinicians make informed decisions faster and with confidence. We’re proud to take another step toward smarter, more efficient neuro-oncology workflows.

Next up in our mTRIAL release preview:
the Unidirectional Feature for RECIST MRI — a key advancement in longitudinal lesion tracking and precision oncology.

Users can now measure lesion diameters with pinpoint accuracy, activate a second viewing window to compare follow-up exams, and adjust views to assess additional lesions — all within one streamlined workflow. Seamless transitions between examinations make longitudinal analysis faster and more intuitive than ever.

October marks Breast Cancer Awareness Month — a global initiative to promote prevention, early detection, and innovative research against breast cancer.

We’re proud to contribute to this mission through our involvement in the Marie-Skłodowska-Curie network BosomShield. Together, we’re advancing breast cancer treatment by integrating clinical, pathological, and radiological data.

Our PhD researchers are developing AI-driven methods for lesion segmentation and classification across multiple imaging modalities — aiming to improve relapse probability prediction and support more personalized care.

Let’s keep pushing boundaries in research and raising awareness.